Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Targeting tumours with genetically enhanced T lymphocytes.

Sadelain M, Rivière I, Brentjens R.

Nat Rev Cancer. 2003 Jan;3(1):35-45. Review.

PMID:
12509765
2.

The role of T lymphocytes in the immunotherapy of tumours.

Brondz BD, Balashov KE.

Biomed Sci. 1991;2(5):441-9. Review.

PMID:
1840832
3.

Cancer immunotherapy: a treatment for the masses.

Blattman JN, Greenberg PD.

Science. 2004 Jul 9;305(5681):200-5. Review.

PMID:
15247469
4.

[Cell therapy in solid tumors].

Ravaud A.

Bull Cancer. 2001 Jan;88(1):91-100. Review. French. No abstract available.

5.

Cellular immunotherapy of cancer.

Yang JC.

Curr Opin Gen Surg. 1994:238-44. Review.

PMID:
7583979
6.

Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.

Rivière I, Sadelain M, Brentjens RJ.

Curr Hematol Rep. 2004 Jul;3(4):290-7. Review.

PMID:
15217559
7.

Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.

Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA.

Semin Oncol. 2015 Aug;42(4):626-39. doi: 10.1053/j.seminoncol.2015.05.005. Epub 2015 Jun 12. Review. No abstract available.

PMID:
26320066
8.

[Cancer immunotherapy: immunologic bases, reality and hopes].

Dietrich PY, Farace F, Caignard A, Escudier B, Triebel F.

Bull Cancer. 1993 Jul;80(7):584-600. Review. French.

PMID:
8204939
9.

Strategies for immunotherapy of cancer.

Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R.

Adv Immunol. 2000;75:235-82. Review. No abstract available.

PMID:
10879286
10.

Immunotherapy of head and neck cancer.

Resser JR, Carbone DP.

Curr Opin Oncol. 1998 May;10(3):226-32. Review.

PMID:
9619359
11.

Immunotherapy II: Antigens, receptors and costimulation.

Searle PF, Young LS.

Cancer Metastasis Rev. 1996 Sep;15(3):329-49. Review.

PMID:
9034595
12.

Signaling defects in anti-tumor T cells.

Frey AB, Monu N.

Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x. Review.

13.

Improving the efficacy and safety of engineered T cell therapy for cancer.

Shi H, Liu L, Wang Z.

Cancer Lett. 2013 Jan 28;328(2):191-7. doi: 10.1016/j.canlet.2012.09.015. Epub 2012 Sep 27. Review.

PMID:
23022475
14.

Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.

Melief CJ.

Adv Cancer Res. 1992;58:143-75. Review. No abstract available.

PMID:
1532109
15.

Can the dual-functional capability of CIK cells be used to improve antitumor effects?

Wang X, Yu W, Li H, Yu J, Zhang X, Ren X, Cao S.

Cell Immunol. 2014 Jan;287(1):18-22. doi: 10.1016/j.cellimm.2013.11.009. Epub 2013 Dec 8. Review.

PMID:
24355711
16.

Adoptive T-cell immunotherapy of cancer.

Li Q, Chang AE.

Cytokines Cell Mol Ther. 1999 Jun;5(2):105-17. Review.

PMID:
10515683
17.

Adoptive cellular immunotherapy of cancer.

Winter H, Fox BA.

Curr Opin Mol Ther. 1999 Feb;1(1):89-97. Review. No abstract available.

PMID:
11249690
18.

Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies.

Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Miyahara E, Toge T.

Hum Cell. 2003 Dec;16(4):183-9. Review.

PMID:
15147038
19.

Regulatory T cells, tumour immunity and immunotherapy.

Zou W.

Nat Rev Immunol. 2006 Apr;6(4):295-307. Review.

PMID:
16557261
20.

Tumor immunotherapy: the tumor cell as an antigen-presenting cell.

Ostrand-Rosenberg S.

Curr Opin Immunol. 1994 Oct;6(5):722-7. Review.

PMID:
7826527

Supplemental Content

Support Center